The Company is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, the Company intends to focus our search on companies in the healthcare industry.
Company profile
Ticker
BLAC, BLACU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Blue Water Biotech, Inc., Blue Water Vaccines Inc.
SEC CIK
Corporate docs
IRS number
845052822
BLAC stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
22 Oct 24
PRE 14A
Preliminary proxy
18 Oct 24
8-K
Entry into a Material Definitive Agreement
15 Oct 24
425
Business combination disclosure
10 Oct 24
8-K
Entry into a Material Definitive Agreement
10 Oct 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Oct 24
8-K
Entry into a Material Definitive Agreement
24 Sep 24
8-K
Other Events
16 Sep 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Aug 24
10-Q
2024 Q2
Quarterly report
19 Aug 24
Latest ownership filings
SC 13G/A
Bellevue Global Life Science Investors LLC
14 Aug 24
3
Sang Hyun Kim
2 Jul 24
3
Phil Geon Lee
4 Jun 24
SC 13G
Bellevue Global Life Science Investors LLC
8 Feb 24
SC 13G/A
Space Summit Capital LLC
5 Feb 24
4
Kuk Hyoun Hwang
27 Mar 23
4
David Jin Yoo
27 Mar 23
4
Change in insider ownership
27 Mar 23
4
Kuk Hyoun Hwang
23 Feb 23
4
Change in insider ownership
23 Feb 23
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 119.12 k | 119.12 k | 119.12 k | 119.12 k | 119.12 k | 119.12 k |
Cash burn (monthly) | (no burn) | (no burn) | 317.03 k | 366.44 k | 472.13 k | 156.74 k |
Cash used (since last report) | n/a | n/a | 1.20 mm | 1.39 mm | 1.79 mm | 594.96 k |
Cash remaining | n/a | n/a | -1.08 mm | -1.27 mm | -1.67 mm | -475.84 k |
Runway (months of cash) | n/a | n/a | -3.4 | -3.5 | -3.5 | -3.0 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 38 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 23.48 bn |
Total shares | 12.85 mm |
Total puts | 0.00 |
Total calls | 311.04 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bellevue Global Life Science Investors | 2.04 mm | $21.96 mm |
Periscope Capital | 1.28 mm | $80.09 mm |
Highbridge Capital Management | 836.47 k | $92.93 mm |
Rivernorth Capital Management | 745.12 k | $2.67 bn |
Polar Asset Management Partners | 720.00 k | $53.08 mm |
Boothbay Fund Management | 622.08 k | $3.39 bn |
Exos Asset Management | 578.90 k | $2.17 bn |
Shaolin Capital Management | 563.87 k | $32.39 mm |
Cowen And | 529.08 k | $2.11 bn |
Wolverine Asset Management | 512.05 k | $2.91 bn |